Vincenzo Volpe

Representative Strategic Company Experience

• Advised Acceleron Pharma on its c. $11.5 billion million sale to Merck
• Advised Aimbridge Hospitality, North America’s largest independent hotel management firm and a portfolio company of Advent International, on the antitrust aspects of its merger with Interstate Hotels & Resorts
• Advised Alibaba:
  • on the merger control aspects of its strategic partnership with Richemont to bring the retail offerings of YOOX Net-A-Porter Group to Chinese consumers (“TMT Deal of the Year”)
  • on its strategic partnership and joint venture (in conjunction with Richemont, the Switzerland-based luxury goods group) with Farfetch Limited, a NYSE-listed leading global online luxury fashion retailer
• Advised Asklepios BioPharmaceutical, a US biopharmaceutical company specialised in the development of gene therapies, on its sale to Bayer AG
• Advised Becton Dickinson on its $4.2 billion acquisition of Edwards Lifesciences' Critical Care business
• Represented HUTCHMED in connection with a worldwide license agreement with Takeda Pharmaceutical for up to $1.13 billion
• Represented Immunogen in its $10.1 billion sale to AbbVie
• Represented Legends Hospitality, a sports and entertainment premium experiences company, in its acquisition of ASM Global to create a global live events company
• Acted for Medtronic:
  • in its acquisition of Intersect ENT for an approximate value of $1.1 billion
  • in its acquisition of Companion Medical, the developer of InPen, a smart insulin pen for the treatment of diabetes
  • on its $1.64 billion acquisition of Mazor Robotics Ltd
  • on the CMA review of its preferred partnership with Animas Corporation
• Advised Provention Bio, Inc., in a sales agreement to global healthcare company Sanofi for approximately $2.9 billion
• Represented Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs
• Acted for Takeda Pharmaceutical Company Limited:
  • on its acquisition of GammaDelta Therapeutics Limited, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy
  • in an exclusive collaboration and license agreement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 for the treatment of Hunter syndrome
• Represented Wieland-Werke AG in its $1.2 billion acquisition of Global Brass and Copper Holdings, Inc.

Representative Private Equity Experience

• Represented Advent International Corp. in its acquisition of Nielsen’s Global Connect business for US$2.7 billion
• Advised Avista Capital Partners:
  • on its sale of Acino, a Swiss pharmaceutical company, to ADQ, a Sovereign Wealth Fund located in Abu Dhabi
  • on its joint acquisition with VHC Investco of Vision Healthcare, one of Europe’s fastest-growing omni-channel and direct-to-consumer health care companies
  • on the antitrust aspects of the sale of Trimb Healthcare to Karo Pharma, cleared subject to divestitures
• Represented Bain Capital in connection with its:
  • $150 million minority investment in Ataccama
  • investment in Enterprise DB
  • €955.3 million acquisition of Caverion Corporation
• Acted for Baring Private Equity Asia on the European Commission review of its and PAI Partners' acquisition of World Freight Company International
• Represented Charlesbank Capital Partners:
  • in the acquisition by its portfolio company Sound United LLC of Bowers & Wilkins, a leading designer and manufacturer of luxury audio products
  • in its investment in Park Place Technologies, a leading global third-party maintenance provider, alongside GTCR
• Acted for CIRCOR International in a take-private sale to global investment firm KKR in a cash transaction valued at approximately $1.6 billion.
• Advised Cove Hill Partners on its $500 million sale of LiveAuctioneers to Auction Technology Group
• Represented CVC Capital Partners and its portfolio company System C on the acquisitions of Clevermed and Oxford Computer Consultants.
• Acted for Genstar Capital:
  • on the acquisition of Lightspeed Systems, the market leader in online student safety and effectiveness
  • on the merger control review of its acquisition of certain assets of Amcor Flexibles
• Advised Inflexion, a UK-headquartered private equity firm, and other shareholders (including the management team) on the sale of Reed & Mackay, a premium corporate travel management and events business, to TripActions, a U.S.-headquartered business travel and spend management platform
• Acted for TPG Inc.:
  • on the sale of Immucor to Werfen for $2 billion
  • on the sale of McAfee Corp’s Consumer business to an investor group for over US$14 billion
  • on the sale of McAfee Corp’s Enterprise business to a consortium led by Symphony Technology Group for US$4 billion

Representative Secondaries Transactions Experience

• Regularly advises an Asian sovereign investor on their primary, co-investment and secondaries programs

Notable transactions in which Vincenzo has been involved prior to joining the firm include:

• Represented Liberty Media Corporation in national merger control approvals of its acquisition of Formula One
• Advised Halliburton in seeking to receive EU merger control approval of its US$28 billion proposed acquisition of Baker Hughes
• Acted for Dresser-Rand in EU and other merger control approvals of its US$7.8 billion merger with Siemens
• Advised a leading electronic commerce and cloud computing company on the compliance of its business strategy with EU competition law
• Advised a major airline in the context of state aid litigation before the General Court of the EU